Carnitine level in Chinese epileptic patients taking sodium valproate

Pediatric Neurology

Volumn 28, Issue 1, 2003, Pages 24-27

  Fung, Eva L W ^a   Tang, Nelson L S ^b   Ho, Chung Shun ^b   Lam, Christopher W K ^b   Fok, Tai Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARNITINE; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CARNITINE DEFICIENCY; CEREBRAL PALSY; CLINICAL ARTICLE; DEMOGRAPHY; DRUG DOSAGE FORM; DRUG SURVEILLANCE PROGRAM; EPILEPSY; FEEDING DISORDER; FEMALE; HUMAN; LOCOMOTION; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARNITINE; CHILD; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC DISEASES; PREVALENCE; RISK FACTORS; VALPROIC ACID;

EID: 0344837408     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(02)00460-5     Document Type: Article

References (17)

1. Van Wouwe J.P. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res. 65:1995;211-214.
2. Opala G., Winter S., Vance C., et al. The effect of valproic acid on plasma carnitine levels. Am J Dis Child. 145:1991;999-1001.
3. Verrotti A., Greco R., Morgese G., Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res. 29:1999;36-40.
4. Hiraoka A., Arato T., Tominaga I. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs. Biol Pharm Bull. 20:1997;91-93.
5. Castro-Gago M., Eiris-Punal J., Novo-Rodriguez M.I., Couceiro J., Camina F., Rodriguez-Segade S. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol. 13:1998;546-549.
6. Igarashi N., Sato T., Kyouya S. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet. Acta Paediatr Jpn. 32:1990;139-145.
7. Hirose S., Mitsudome A., Yasumoto S., Ogawa A., Muta Y., Tomoda Y. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics. 101:1998;E9.
8. Li J., Norwood D.L., Mao L.F., Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry. 30:1991;388-394.
9. Becker C.M., Harris R.A. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys. 223:1983;381-392.
10. Matsuda I., Ohtani Y. Carnitine status in Reye and Reye-like syndromes. Pediatr Neurol. 2:1986;90-94.
11. Coulter D.L. Carnitine deficiency A possible mechanism for valproate hepatotoxicity. Lancet. 1:1984;689.
12. Bohan T.P., Helton E., McDonald I., et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 56:(10):2001;1405-1409.
13. Coulter D.L. Carnitine deficiency in epilepsy Risk factors and treatment. J Child Neurol. 10:(Suppl 2):1995;S32-39.
14. De Vivo D.C., Bohan T.P., Coulter D.L., et al. L-carnitine supplementation in childhood epilepsy Current perspectives. Epilepsia. 39:1998;1216-1225.
15. Shapira Y., Gutman A. Muscle carnitine deficiency in patients using valproic acid. J Pediatr. 118:1991;646-649.
16. Freeman J.M., Vining E.P., Cost S., Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. Pediatrics. 93:1994;893-895.
17. Kelly R.I. The role of carnitine supplementation in valproic acid therapy. Pediatrics. 93:1994;891-892.